Septerna (SEPN) Competitors $9.06 -0.36 (-3.82%) Closing price 04:00 PM EasternExtended Trading$8.80 -0.26 (-2.81%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock SEPN vs. ARQT, AGIO, SDGR, IRON, BHC, CNTA, INDV, BHVN, IDYA, and EWTXShould you be buying Septerna stock or one of its competitors? The main competitors of Septerna include Arcutis Biotherapeutics (ARQT), Agios Pharmaceuticals (AGIO), Schrödinger (SDGR), Disc Medicine (IRON), Bausch Health Companies (BHC), Centessa Pharmaceuticals (CNTA), Indivior (INDV), Biohaven (BHVN), IDEAYA Biosciences (IDYA), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry. Septerna vs. Arcutis Biotherapeutics Agios Pharmaceuticals Schrödinger Disc Medicine Bausch Health Companies Centessa Pharmaceuticals Indivior Biohaven IDEAYA Biosciences Edgewise Therapeutics Arcutis Biotherapeutics (NASDAQ:ARQT) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation, community ranking and risk. Does the MarketBeat Community prefer ARQT or SEPN? Arcutis Biotherapeutics received 66 more outperform votes than Septerna when rated by MarketBeat users. Likewise, 67.92% of users gave Arcutis Biotherapeutics an outperform vote while only 66.67% of users gave Septerna an outperform vote. CompanyUnderperformOutperformArcutis BiotherapeuticsOutperform Votes7267.92% Underperform Votes3432.08% SepternaOutperform Votes666.67% Underperform Votes333.33% Is ARQT or SEPN more profitable? Septerna has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Septerna's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcutis Biotherapeutics-140.97% -119.11% -45.95% Septerna N/A N/A N/A Does the media refer more to ARQT or SEPN? In the previous week, Arcutis Biotherapeutics and Arcutis Biotherapeutics both had 14 articles in the media. Arcutis Biotherapeutics' average media sentiment score of 1.63 beat Septerna's score of 0.53 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Septerna 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, ARQT or SEPN? Septerna has lower revenue, but higher earnings than Arcutis Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcutis Biotherapeutics$212.82M7.69-$262.14M-$1.04-13.19Septerna$1.08M371.66N/AN/AN/A Do analysts rate ARQT or SEPN? Arcutis Biotherapeutics currently has a consensus target price of $18.80, indicating a potential upside of 37.01%. Septerna has a consensus target price of $27.00, indicating a potential upside of 200.84%. Given Septerna's higher possible upside, analysts plainly believe Septerna is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Septerna 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryArcutis Biotherapeutics beats Septerna on 6 of the 11 factors compared between the two stocks. Get Septerna News Delivered to You Automatically Sign up to receive the latest news and ratings for SEPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEPN vs. The Competition Export to ExcelMetricSepternaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$419.34M$6.54B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E RatioN/A9.1426.7920.05Price / Sales390.08255.59394.72116.44Price / CashN/A65.8538.2534.62Price / BookN/A6.546.864.61Net IncomeN/A$143.51M$3.22B$248.19M7 Day Performance-7.28%5.60%6.83%2.97%1 Month Performance60.48%10.06%13.73%16.58%1 Year PerformanceN/A-0.86%18.22%8.16% Septerna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEPNSepterna2.0614 of 5 stars$9.06-3.8%$27.00+198.0%N/A$403.32M$1.08M0.00N/AEarnings ReportAnalyst RevisionGap DownARQTArcutis Biotherapeutics2.779 of 5 stars$14.64+3.8%$18.80+28.4%+55.2%$1.75B$212.82M-8.18150News CoveragePositive NewsInsider TradeGap DownAGIOAgios Pharmaceuticals4.0346 of 5 stars$29.84+2.3%$56.00+87.7%-9.1%$1.73B$37.04M2.63390Positive NewsAnalyst DowngradeSDGRSchrödinger2.9603 of 5 stars$23.56-0.1%$32.80+39.2%-4.7%$1.72B$230.49M-10.07790News CoveragePositive NewsIRONDisc Medicine2.9064 of 5 stars$49.69+3.3%$98.80+98.8%+54.7%$1.72BN/A-12.4830BHCBausch Health Companies4.1712 of 5 stars$4.64-0.6%$7.42+59.8%-28.0%$1.68B$9.73B-38.6619,900Gap UpCNTACentessa Pharmaceuticals3.5956 of 5 stars$12.26-2.0%$27.00+120.2%+51.4%$1.67B$15M-8.01200Positive NewsInsider TradeAnalyst RevisionGap UpINDVIndivior3.3063 of 5 stars$11.68+3.0%$15.00+28.4%-33.1%$1.61B$1.17B-33.371,164News CoveragePositive NewsBHVNBiohaven3.4882 of 5 stars$15.75-1.7%$59.46+277.5%-58.7%$1.61BN/A-1.68239Analyst DowngradeGap DownIDYAIDEAYA Biosciences3.7852 of 5 stars$18.08+1.5%$54.27+200.2%-51.3%$1.58B$7M-5.4880Positive NewsEWTXEdgewise Therapeutics2.9231 of 5 stars$14.79+0.1%$40.22+172.0%-20.8%$1.55BN/A-9.8660Positive News Related Companies and Tools Related Companies ARQT Competitors AGIO Competitors SDGR Competitors IRON Competitors BHC Competitors CNTA Competitors INDV Competitors BHVN Competitors IDYA Competitors EWTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SEPN) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Septerna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Septerna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SEPN Stock Free SEPN Stock Alerts